查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1880403

荷爾蒙平衡療法市場預測至2032年：按荷爾蒙類型、配方、技術、應用、最終用戶和地區分類的全球分析

Hormone-Balancing Therapeutics Market Forecasts to 2032 - Global Analysis By Hormone Type, Formulation, Technology, Application, End User, and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，全球荷爾蒙平衡療法市場預計將在 2025 年達到 236 億美元，並在 2032 年達到 394 億美元，在預測期內以 7.6% 的複合年成長率成長。

荷爾蒙平衡療法包括藥物和生物同源療法，旨在調節內分泌功能，恢復患者的荷爾蒙平衡。這些治療方法針對甲狀腺疾病、更年期症狀、腎上腺功能不全和代謝失調等疾病。透過口服、注射或經皮，這些療法可以穩定荷爾蒙水平，從而改善情緒、精力、生殖功能和代謝過程。生物技術和個人化醫療的進步拓展了這一領域，使得客製化的治療方案成為可能，這些方案既能滿足個體的荷爾蒙需求，又能最大限度地減少副作用。

內分泌學會報告稱，由於更年期症狀、甲狀腺疾病和代謝紊亂的個人化治療方法，患者對生物同源荷爾蒙療法的需求正在成長。

全球內分泌疾病發生率呈上升趨勢

甲狀腺功能障礙、糖尿病和腎上腺功能不全等內分泌疾病的增加是推動荷爾蒙平衡療法市場發展的主要因素。文明病的增加、人口老化以及遺傳易感性也推動了對有效荷爾蒙療法的需求。隨著越來越多的患者需要長期治療，製藥公司正在投資研發先進的製劑技術和給藥系統。全球內分泌疾病負擔的日益加重確保了對荷爾蒙平衡療法的持續需求，使其成為現代醫療保健的關鍵組成部分，並成為市場擴張的主要驅動力。

對荷爾蒙療法進行嚴格的安全性評估

荷爾蒙療法市場面臨的主要阻礙因素是其嚴格的安全性評估要求。監管機構制定了嚴格的測試通訊協定，以確保療效並最大限度地降低副作用風險。漫長的核准流程延緩了產品上市，並增加了研發成本。此外，人們對長期安全性的擔憂，尤其是在生殖和代謝健康方面，也阻礙了荷爾蒙療法的快速普及。雖然安全標準至關重要，但它們也阻礙了創新和商業化，減緩了荷爾蒙平衡療法市場新治療方法的推出速度。

利用生物標記分析進行個人化給藥

基於生物標記分析的個人化給藥方案蘊藏著巨大的發展機會。精準醫療的進步使臨床醫生能夠根據個別生物標記物譜客製化荷爾蒙療法，從而提高療效並減少副作用。透過利用遺傳、代謝和內分泌標誌物，個人化給藥方案可確保最佳治療效果。這種方法在甲狀腺疾病、糖尿病和更年期相關疾病的治療中尤其重要。隨著生物標記驅動的分析技術日益普及，製藥公司和醫療機構可以擴大其應用範圍，將個人化給藥方案打造成為荷爾蒙平衡療法領域的一項變革性機會。

對不利事件的擔憂阻礙了其廣泛應用。

對不利事件的擔憂仍然是荷爾蒙平衡療法市場面臨的一大威脅。荷爾蒙療法可能引起心血管風險、代謝失調和生殖併發症等副作用，這令患者和醫療服務提供者都心存疑慮。負面認知和訴訟風險進一步阻礙了荷爾蒙療法的普及，尤其是在監管嚴格的地區。除非治療方法得到改進以最大限度地減少不良反應，否則這些擔憂可能會減緩市場滲透。透過創新和透明的臨床數據來解決安全性問題，對於克服這一持續存在的威脅至關重要。

新冠疫情的感染疾病：

新冠疫情導致供應鏈中斷和臨床試驗延期，減緩了荷爾蒙平衡療法的研發和推廣。然而，這場危機也凸顯了慢性內分泌疾病管理的重要性，揭示了荷爾蒙失衡患者發生併發症的風險更高。遠端醫療的普及加速了荷爾蒙療法的推廣，而數位健康工具則支持了遠端監測和個人化給藥。隨著疫情後恢復期對更具韌性的醫療保健解決方案的需求不斷成長，激素平衡療法在數位整合的醫療保健生態系統中，被視為長期患者管理的重要組成部分。

預計在預測期內，甲狀腺荷爾蒙療法領域將佔據最大的市場佔有率。

預計在預測期內，甲狀腺荷爾蒙療法領域將佔據最大的市場佔有率。這主要歸因於甲狀腺疾病在全球範圍內的高發生率。甲狀腺甲狀腺機能低下症和甲狀腺功能亢進症等疾病需要持續的治療性介入，從而推動了對有效激素平衡解決方案的需求。公眾意識的提高、診斷能力的提升以及治療依從性的增強，都主導了甲狀腺治療成為市場領導者。口服和注射劑型藥物的進步進一步鞏固了該領域的地位，確保其繼續成為整體市場收入的最大貢獻者。

預計在預測期內，口服藥物細分市場將呈現最高的複合年成長率。

由於口服藥物給藥方便、患者偏好度高且成本效益高，預計在預測期內，口服藥物細分市場將保持最高的成長率。口服製劑為慢性內分泌疾病患者提供了方便的給藥選擇，並提高了患者的藥物順從性。緩釋性技術的進步和生物利用度的最佳化進一步提升了治療效果。隨著醫療保健系統將可近性和可負擔性放在首位，口服藥物越來越受到患者的青睞，逐漸取代了侵入性治療方式，成為荷爾蒙平衡療法市場中成長最快的細分市場。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這主要歸功於該地區龐大的患者群體、內分泌疾病盛行率的上升以及不斷完善的醫療基礎設施。中國、印度和日本等國家正大力投資於診斷和治療技術的進步，從而促進了荷爾蒙平衡療法的普及。日益增強的公眾意識、政府的支持措施以及治療方法的可負擔性不斷提高，進一步推動了該地區的需求。亞太地區的龐大規模和快速的醫療現代化使其在全球荷爾蒙平衡療法市場中佔據主導地位。

年複合成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於其先進的醫療基礎設施、強勁的研發投入以及精準醫療的廣泛應用。大型製藥公司的存在和健全的法規結構正在加速荷爾蒙療法的創新。內分泌疾病盛行率的上升，以及對個人化給藥和基於生物標記的治療日益成長的需求，正在推動該領域的快速成長。對病患安全、創新和可近性的高度重視，使北美成為該市場成長最快的地區。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家的市場規模和複合年成長率進行估算和預測（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球荷爾蒙平衡療法市場（以荷爾蒙類型分類）

  • 介紹
  • 雌激素調變器
  • 睪固酮調節劑
  • 甲狀腺荷爾蒙療法
  • 皮質醇平衡藥物
  • 胰島素和代謝激素
  • 基於胜肽的荷爾蒙療法

6. 全球荷爾蒙平衡療法市場（依配方分類）

  • 介紹
  • 口服藥物
  • 注射療法
  • 經皮吸收貼片
  • 嵌入式顆粒
  • 舌下片
  • 外用凝膠和乳膏

7. 全球荷爾蒙平衡療法市場（依技術分類）

  • 介紹
  • 生物同源荷爾蒙合成
  • AI誘導的內分泌調節
  • 標靶遞送系統
  • 基因組客製化療法
  • 緩釋性遞送技術
  • 精準診斷整合

8. 全球荷爾蒙平衡療法市場（按應用領域分類）

  • 介紹
  • 更年期管理
  • 代謝紊亂
  • 甲狀腺功能障礙
  • 最佳化生育能力
  • 壓力與腎上腺調節
  • 性別重置治療支持

9. 全球荷爾蒙平衡療法市場（按最終用戶分類）

  • 介紹
  • 醫院
  • 專科診所
  • 遠端醫療提供者
  • 藥局
  • 研究所

第10章 全球荷爾蒙平衡療法市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章：企業概況

  • Pfizer
  • Novo Nordisk
  • Bayer
  • Abbott Laboratories
  • Roche
  • Eli Lilly and Company
  • Mylan
  • Merck
  • Viatris
  • Amgen
  • Novartis
  • AbbVie
  • Hisamitsu Pharmaceutical
  • Endo International
  • TherapeuticsMD
  • Ascend Therapeutics
  • BioTE Medical
  • Teva Pharmaceuticals
Product Code: SMRC32489

According to Stratistics MRC, the Global Hormone-Balancing Therapeutics Market is accounted for $23.6 billion in 2025 and is expected to reach $39.4 billion by 2032 growing at a CAGR of 7.6% during the forecast period. Hormone-balancing therapeutics encompass pharmaceutical and bioidentical treatments designed to regulate endocrine function and restore hormonal equilibrium in patients. These therapies target conditions such as thyroid disorders, menopause, adrenal insufficiency, and metabolic imbalances. Delivered through oral, injectable, or transdermal formulations, they stabilize hormone levels to improve mood, energy, reproductive health, and metabolic processes. Advances in biotechnology and personalized medicine have expanded this field, enabling tailored regimens that minimize side effects while addressing individual hormonal needs.

According to Endocrine Society reports, patient demand for bioidentical hormone therapies is rising, driven by personalized treatment approaches that address menopause, thyroid disorders, and metabolic imbalances.

Market Dynamics:

Driver:

Growing prevalence of endocrine disorders globally

The rising prevalence of endocrine disorders such as thyroid dysfunction, diabetes, and adrenal imbalances is a major driver of the hormone-balancing therapeutics market. Increasing lifestyle-related health issues, aging populations, and genetic predispositions are fueling demand for effective hormone therapies. With more patients requiring long-term management, pharmaceutical companies are investing in advanced formulations and delivery systems. This growing global burden of endocrine disorders ensures sustained demand, positioning hormone-balancing therapeutics as a critical component of modern healthcare and a key driver of market expansion.

Restraint:

Strict safety evaluation for hormone therapies

A significant restraint for the market is the stringent safety evaluation required for hormone therapies. Regulatory authorities impose rigorous testing protocols to ensure efficacy and minimize risks of adverse effects. These lengthy approval processes delay product launches and increase development costs. Additionally, concerns over long-term safety, particularly in reproductive and metabolic health, limit rapid adoption. While safety standards are essential, they create barriers for innovation and commercialization, slowing the pace of new therapeutic introductions in the hormone-balancing therapeutics market.

Opportunity:

Personalized dosing using biomarker analytics

Personalized dosing through biomarker analytics presents a strong opportunity for growth. Advances in precision medicine allow clinicians to tailor hormone therapies based on individual biomarker profiles, improving efficacy and reducing side effects. By leveraging genetic, metabolic, and endocrine markers, personalized dosing ensures optimal treatment outcomes. This approach is particularly valuable in managing thyroid disorders, diabetes, and menopause-related conditions. As biomarker-driven analytics become more accessible, pharmaceutical companies and healthcare providers can expand adoption, positioning personalized dosing as a transformative opportunity in hormone-balancing therapeutics.

Threat:

Adverse-event concerns reducing adoption

Concerns over adverse events remain a critical threat to the hormone-balancing therapeutics market. Hormone therapies can cause side effects such as cardiovascular risks, metabolic imbalances, or reproductive complications, leading to hesitancy among patients and providers. Negative perceptions and litigation risks further discourage adoption, particularly in regions with strict regulatory oversight. Unless therapies are refined to minimize adverse outcomes, these concerns may slow market penetration. Addressing safety through innovation and transparent clinical data will be essential to overcoming this persistent threat.

Covid-19 Impact:

The Covid-19 pandemic disrupted supply chains and delayed clinical trials, slowing the development and distribution of hormone-balancing therapies. However, the crisis also highlighted the importance of managing chronic endocrine disorders, as patients with imbalances faced higher risks of complications. Telemedicine adoption accelerated access to hormone therapies, while digital health tools supported remote monitoring and personalized dosing. Post-pandemic recovery has reinforced demand for resilient healthcare solutions, positioning hormone-balancing therapeutics as essential for long-term patient management in a digitally integrated healthcare ecosystem.

The thyroid hormone therapies segment is expected to be the largest during the forecast period

The thyroid hormone therapies segment is expected to account for the largest market share during the forecast period, resulting from the high prevalence of thyroid disorders worldwide. Conditions such as hypothyroidism and hyperthyroidism require consistent therapeutic intervention, driving demand for effective hormone-balancing solutions. With growing awareness, improved diagnostic capabilities, and rising treatment adherence, thyroid therapies dominate the market. Pharmaceutical advancements in oral and injectable formulations further strengthen this segment's position, ensuring it remains the largest contributor to overall market revenues.

The oral medications segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oral medications segment is predicted to witness the highest growth rate, propelled by ease of administration, patient preference, and cost-effectiveness. Oral formulations provide convenient dosing options, improving compliance among patients with chronic endocrine disorders. Advances in controlled-release technologies and bioavailability optimization further enhance therapeutic outcomes. As healthcare systems prioritize accessibility and affordability, oral medications are increasingly favored over invasive alternatives, positioning them as the fastest-growing segment in the hormone-balancing therapeutics market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, Asia Pacific region is expected to hold the largest market share, attributed to its large patient population, rising prevalence of endocrine disorders, and expanding healthcare infrastructure. Countries such as China, India, and Japan are investing heavily in diagnostic and therapeutic advancements, driving adoption of hormone-balancing treatments. Growing awareness, supportive government initiatives, and increasing affordability of therapies further strengthen regional demand. Asia Pacific's scale and rapid healthcare modernization ensure its dominance in the global hormone-balancing therapeutics market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with advanced healthcare infrastructure, strong R&D investments, and widespread adoption of precision medicine. The presence of leading pharmaceutical companies and robust regulatory frameworks accelerates innovation in hormone therapies. Rising prevalence of endocrine disorders, coupled with growing demand for personalized dosing and biomarker-driven treatments, fuels rapid growth. With strong emphasis on patient safety, innovation, and accessibility, North America is positioned as the fastest-growing region in this market.

Key players in the market

Some of the key players in Hormone-Balancing Therapeutics Market include Pfizer, Novo Nordisk, Bayer, Abbott Laboratories, Roche, Eli Lilly and Company, Mylan, Merck, Viatris, Amgen, Novartis, AbbVie, Hisamitsu Pharmaceutical, Endo International, TherapeuticsMD, Ascend Therapeutics, BioTE Medical, and Teva Pharmaceuticals.

Key Developments:

In October 2025, Pfizer highlighted its strategic commitment to enhancing women's health through innovative hormone replacement therapies, emphasizing improved patient outcomes during its Q1 2025 earnings call.

In July 2025, Texas Star Pharmacy launched a new line of bio-identical hormone pellets, offering a convenient and sustained-release alternative to daily pills, creams, or injections for hormone replacement therapy.

In February 2025, Cosette Pharmaceuticals acquired Mayne Pharma's women's health portfolio for USD 430 million, adding 12 patent-protected hormone products, including BIJUVA and IMVEXXY.

Hormone Types Covered:

  • Estrogen Modulators
  • Testosterone Regulators
  • Thyroid Hormone Therapies
  • Cortisol Balancing Drugs
  • Insulin & Metabolic Hormones
  • Peptide-Based Hormone Therapies

Formulations Covered:

  • Oral Medications
  • Injectable Therapies
  • Transdermal Patches
  • Implantable Pellets
  • Sublingual Tablets
  • Topical Gels & Creams

Technologies Covered:

  • Bioidentical Hormone Synthesis
  • AI-Guided Endocrine Modulation
  • Targeted Delivery Systems
  • Genomic-Customized Therapies
  • Slow-Release Delivery Tech
  • Precision Diagnostics Integration

Applications Covered:

  • Menopause Management
  • Metabolic Disorders
  • Thyroid Dysfunction
  • Fertility Optimization
  • Stress & Adrenal Regulation
  • Gender-Affirming Therapy Support

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Telehealth Providers
  • Pharmacies
  • Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hormone-Balancing Therapeutics Market, By Hormone Type

  • 5.1 Introduction
  • 5.2 Estrogen Modulators
  • 5.3 Testosterone Regulators
  • 5.4 Thyroid Hormone Therapies
  • 5.5 Cortisol Balancing Drugs
  • 5.6 Insulin & Metabolic Hormones
  • 5.7 Peptide-Based Hormone Therapies

6 Global Hormone-Balancing Therapeutics Market, By Formulation

  • 6.1 Introduction
  • 6.2 Oral Medications
  • 6.3 Injectable Therapies
  • 6.4 Transdermal Patches
  • 6.5 Implantable Pellets
  • 6.6 Sublingual Tablets
  • 6.7 Topical Gels & Creams

7 Global Hormone-Balancing Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 Bioidentical Hormone Synthesis
  • 7.3 AI-Guided Endocrine Modulation
  • 7.4 Targeted Delivery Systems
  • 7.5 Genomic-Customized Therapies
  • 7.6 Slow-Release Delivery Tech
  • 7.7 Precision Diagnostics Integration

8 Global Hormone-Balancing Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Menopause Management
  • 8.3 Metabolic Disorders
  • 8.4 Thyroid Dysfunction
  • 8.5 Fertility Optimization
  • 8.6 Stress & Adrenal Regulation
  • 8.7 Gender-Affirming Therapy Support

9 Global Hormone-Balancing Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Telehealth Providers
  • 9.5 Pharmacies
  • 9.6 Research Institutes

10 Global Hormone-Balancing Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer
  • 12.2 Novo Nordisk
  • 12.3 Bayer
  • 12.4 Abbott Laboratories
  • 12.5 Roche
  • 12.6 Eli Lilly and Company
  • 12.7 Mylan
  • 12.8 Merck
  • 12.9 Viatris
  • 12.10 Amgen
  • 12.11 Novartis
  • 12.12 AbbVie
  • 12.13 Hisamitsu Pharmaceutical
  • 12.14 Endo International
  • 12.15 TherapeuticsMD
  • 12.16 Ascend Therapeutics
  • 12.17 BioTE Medical
  • 12.18 Teva Pharmaceuticals

List of Tables

  • Table 1 Global Hormone-Balancing Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hormone-Balancing Therapeutics Market Outlook, By Hormone Type (2024-2032) ($MN)
  • Table 3 Global Hormone-Balancing Therapeutics Market Outlook, By Estrogen Modulators (2024-2032) ($MN)
  • Table 4 Global Hormone-Balancing Therapeutics Market Outlook, By Testosterone Regulators (2024-2032) ($MN)
  • Table 5 Global Hormone-Balancing Therapeutics Market Outlook, By Thyroid Hormone Therapies (2024-2032) ($MN)
  • Table 6 Global Hormone-Balancing Therapeutics Market Outlook, By Cortisol Balancing Drugs (2024-2032) ($MN)
  • Table 7 Global Hormone-Balancing Therapeutics Market Outlook, By Insulin & Metabolic Hormones (2024-2032) ($MN)
  • Table 8 Global Hormone-Balancing Therapeutics Market Outlook, By Peptide-Based Hormone Therapies (2024-2032) ($MN)
  • Table 9 Global Hormone-Balancing Therapeutics Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 10 Global Hormone-Balancing Therapeutics Market Outlook, By Oral Medications (2024-2032) ($MN)
  • Table 11 Global Hormone-Balancing Therapeutics Market Outlook, By Injectable Therapies (2024-2032) ($MN)
  • Table 12 Global Hormone-Balancing Therapeutics Market Outlook, By Transdermal Patches (2024-2032) ($MN)
  • Table 13 Global Hormone-Balancing Therapeutics Market Outlook, By Implantable Pellets (2024-2032) ($MN)
  • Table 14 Global Hormone-Balancing Therapeutics Market Outlook, By Sublingual Tablets (2024-2032) ($MN)
  • Table 15 Global Hormone-Balancing Therapeutics Market Outlook, By Topical Gels & Creams (2024-2032) ($MN)
  • Table 16 Global Hormone-Balancing Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Hormone-Balancing Therapeutics Market Outlook, By Bioidentical Hormone Synthesis (2024-2032) ($MN)
  • Table 18 Global Hormone-Balancing Therapeutics Market Outlook, By AI-Guided Endocrine Modulation (2024-2032) ($MN)
  • Table 19 Global Hormone-Balancing Therapeutics Market Outlook, By Targeted Delivery Systems (2024-2032) ($MN)
  • Table 20 Global Hormone-Balancing Therapeutics Market Outlook, By Genomic-Customized Therapies (2024-2032) ($MN)
  • Table 21 Global Hormone-Balancing Therapeutics Market Outlook, By Slow-Release Delivery Tech (2024-2032) ($MN)
  • Table 22 Global Hormone-Balancing Therapeutics Market Outlook, By Precision Diagnostics Integration (2024-2032) ($MN)
  • Table 23 Global Hormone-Balancing Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Hormone-Balancing Therapeutics Market Outlook, By Menopause Management (2024-2032) ($MN)
  • Table 25 Global Hormone-Balancing Therapeutics Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
  • Table 26 Global Hormone-Balancing Therapeutics Market Outlook, By Thyroid Dysfunction (2024-2032) ($MN)
  • Table 27 Global Hormone-Balancing Therapeutics Market Outlook, By Fertility Optimization (2024-2032) ($MN)
  • Table 28 Global Hormone-Balancing Therapeutics Market Outlook, By Stress & Adrenal Regulation (2024-2032) ($MN)
  • Table 29 Global Hormone-Balancing Therapeutics Market Outlook, By Gender-Affirming Therapy Support (2024-2032) ($MN)
  • Table 30 Global Hormone-Balancing Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Hormone-Balancing Therapeutics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Hormone-Balancing Therapeutics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 33 Global Hormone-Balancing Therapeutics Market Outlook, By Telehealth Providers (2024-2032) ($MN)
  • Table 34 Global Hormone-Balancing Therapeutics Market Outlook, By Pharmacies (2024-2032) ($MN)
  • Table 35 Global Hormone-Balancing Therapeutics Market Outlook, By Research Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.